Anna M. Ifarraguerri, MD; Theodore Quan, MD; Alisa Malyavko, MD; Alex Gu, MD; Michael S. Collins, MD; Patrick Siparsky, MD; Jesse E. Otero, MD; and Bryan M. Saltzman, MD
Is Metabolic Syndrome an Independent Risk Factor for Complications Following Patellofemoral Arthroplasty? A NSQIP Review of 1,618 Patients
$25.00
Metabolic syndrome (MetS) is a cluster of metabolic abnormalities including hypertension, insulin resistance, and central obesity that collectively increase patient risk of morbidity and mortality. This study evaluated the clinical impact of metabolic syndrome on 30-day outcomes following patellofemoral arthroplasty (PFA). From 2007 – 2019, patients undergoing PFA with and without metabolic syndrome in the National Surgical Quality Improvement Program (NSQIP) database were identified and the 30-day complications were assessed. Of 1,618 patients undergoing PFA, 1,443 patients (89.2%) did not have metabolic syndrome, whereas 175 patients (10.8%) did. Following adjustment on multivariate analysis, patients with metabolic syndrome had an increased risk of urinary tract infection (odds ratio [OR] 4.54; p = 0.028), postoperative transfusion (OR 2.05; p = 0.008), and an increased length of stay (OR 1.75; p = 0.007). Patients with metabolic syndrome are at an increased risk of 30-day postoperative complications following PFA. Future risk-adjusted reimbursement models should consider the impact that comorbid conditions such as MetS have on patient outcomes. Level of Evidence: III (Journal of Surgical Orthopaedic
Advances 35(3):138–141, 2026)
Key words: patellofemoral arthroplasty, metabolic syndrome, complications